Fig. 7

PCNA staining in lung epithelium and neoplasia. A Bar graph of PCNA LI (%) data from the lung parenchyma and tumors (adenoma/carcinoma) in the different groups; ****: significance vs. G2 at P ≤ 0.00001; ****: significant vs. G6 at P ≤ 0.00001; B–S: photomicrographs showing PCNA IHC staining patterns in the different groups. B Normal mouse lung epithelium from Group 1 showing low PCNA IHC staining affinity; C alveolar epithelial hyperplasia from Group 2 with a marked increase of PCNA immunostaining D, E lung epithelium from Groups 3 and 4 treated with BPE and Avastin, respectively; F lung epithelium from Group 5 treated with BPENP; G lung epithelium from Group 6 treated with BPENP + Avastin. Notice the reduced thickness of the alveolar epithelial hyperplasia after all treatments, particularly in Group 6, compared to the normal control. H Bronchioloalveolar adenoma from Group 2, I magnified portion of G. Notice the reduced size of the adenomas after the treatment with BPE J Avastin K BPENP (L), or both (M). N bronchioloalveolar adenocarcinomas from Group 2; O a magnified portion of M. Treatment with BPE (P), Avastin (Q), BPENP (R), or both (S) reduced the sizes of the adenocarcinomas when compared to that in Group 2. PCNA